🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPhase 3 trial enrollment guide — my results so far Page 2

Phase 3 trial enrollment guide — my results so far

josh_phd_bmore Mon, Feb 23, 2026 at 12:22 PM 21 replies 1,019 viewsPage 2 of 5
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Feb 24, 2026 at 2:05 AM#6
MikeFit_NJ said:
Relative and absolute effects need reading together.

Pushing back on MikeFit_NJ here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

27 5Dr.LeslieOBGYN, MikeNYC_runner and 24 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Feb 24, 2026 at 7:31 AM#7
josh_phd_bmore said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.72 (95% CI 0.67-0.82), I²=30%. This is a robust and consistent effect.

28 6VanRx_Mike, steve_okc, dave_SLC and 25 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Feb 24, 2026 at 12:57 PM#8
PurityPaulOR said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

Last edited: Feb 24, 2026 at 6:57 PM
29 7tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 26 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
ChrisMacros
Member
567
2,345
Sep 2024
Michigan
Feb 24, 2026 at 6:22 PM#9

Following on from LarryQC_SD — and this may be the naive question:

Was that from a primary source or from a summary of one?

Last edited: Feb 24, 2026 at 9:22 PM
30 8LibrarianMeg, bri_stats, pete_manc_UK and 27 others
Reply Quote Save Share Report
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Feb 25, 2026 at 8:23 PM#10

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

32 7tampaLisa73, KarenAZ_mom, zoe_NC and 29 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register